Welcome to our dedicated page for Bristol-Myers Squibb news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb stock.
Bristol Myers Squibb reports news on its pharmaceutical portfolio across oncology, cardiovascular disease and immunology, including regulatory decisions, clinical trial data, commercial access programs and product collaborations. Company updates include Sotyktu (deucravacitinib), a selective TYK2 inhibitor approved in the European Union for active psoriatic arthritis, and Eliquis (apixaban), an oral anticoagulant marketed through the Bristol Myers Squibb-Pfizer alliance.
Recurring developments also cover quarterly financial results, investor conference participation, debt and capital-market activity, research collaborations in cardiovascular and precision-medicine programs, and community initiatives tied to multiple myeloma care. The company’s news flow combines product-specific regulatory milestones with broader disclosures on operating performance and pipeline partnerships.
Bristol Myers Squibb (NYSE: BMY) announced the FDA's acceptance of its supplemental new drug application (sNDA) for CAMZYOS® (mavacamten), aiming to expand its indication to reduce the need for septal reduction therapy (SRT) in patients with obstructive hypertrophic cardiomyopathy (HCM). The sNDA is based on the successful Phase 3 VALOR-HCM study, which met all primary and secondary endpoints with no new safety signals. The FDA has set a Prescription Drug User Fee Act goal date of June 16, 2023.
Bristol Myers Squibb (NYSE: BMY) announced significant results from the Phase 3 CheckMate -76K trial, demonstrating that Opdivo (nivolumab) as an adjuvant therapy improved recurrence-free survival (RFS) for stage IIB and IIC melanoma patients. Opdivo reduced recurrence or death risk by 58% compared to placebo (HR 0.42; p 0.0001) with 12-month RFS rates of 89% versus 79%, respectively. The safety profile was consistent with previous studies, with grade 3/4 treatment-related adverse events at 10% for Opdivo. These results highlight Opdivo's potential as a crucial treatment option for melanoma patients.
Bristol Myers Squibb (NYSE:BMY) announced changes to the dial-in and replay information for its third quarter 2022 earnings conference call set for October 26, 2022, at 8:00 a.m. ET. Investors can participate through a live webcast or by phone, with details provided for dial-in access. A replay will be available starting at 11:30 a.m. ET on the same day until November 9, 2022. The company remains focused on its mission to deliver innovative medicines for serious diseases.
Exelixis has expanded its collaboration with Bristol-Myers Squibb to include a fixed-dose combination of nivolumab and relatlimab in the ongoing phase 1b STELLAR-002 clinical trial. This trial is evaluating XL092, Exelixis' next-generation oral tyrosine kinase inhibitor (TKI), combined with immune checkpoint inhibitors for advanced solid tumors. The study aims to determine the optimal dosing regimen across various combinations, enhancing treatment options for patients.
Bristol Myers Squibb (BMY) has received European Commission approval for Opdualag, a first-in-class combination treatment of nivolumab and relatlimab, for advanced melanoma in patients aged 12 and older with PD-L1 expression 1%. This breakthrough comes from the RELATIVITY-047 trial, which showed Opdualag more than doubled median progression-free survival (PFS) to 6.7 months compared to 3.0 months for nivolumab alone. No new safety concerns were identified. This approval marks a significant advancement in melanoma treatment options within the EU, expanding patient access across member states.
Bristol Myers Squibb (NYSE: BMY) announced that the Phase 3 CheckMate -76K trial for Opdivo (nivolumab) in stage IIB/C melanoma has met its primary endpoint with a significant improvement in recurrence-free survival at a pre-specified interim analysis. The trial showed no new safety signals. Approximately one-third of stage IIB and half of stage IIC melanoma patients may experience recurrence within five years post-surgery. Opdivo's results offer potential advancements in cancer treatment, targeting earlier disease stages to improve patient outcomes.
Bristol Myers Squibb (NYSE: BMY) has announced a quarterly dividend of $0.54 per share, payable on November 1, 2022, to stockholders of record by October 7, 2022. Additionally, a dividend of $0.50 per share on its convertible preferred stock will be paid on December 1, 2022, to stockholders on record by November 8, 2022. This decision reflects the company's commitment to returning value to its shareholders while supporting its mission to develop innovative medicines.
Bristol Myers Squibb (NYSE:BMY) announced positive two-year results from the POETYK PSO long-term extension trial for Sotyktu™ (deucravacitinib), showing maintained efficacy in treating moderate-to-severe plaque psoriasis. Response rates at 112 weeks were 82.4% for PASI 75 and 55.2% for PASI 90. The data were presented at the 2022 European Academy of Dermatology and Venereology Congress, underscoring the company's commitment to dermatology research. These findings support Sotyktu’s role as a promising oral therapy for patients with psoriasis.
Bristol Myers Squibb's Sotyktu™ (deucravacitinib) has received FDA approval as the first oral, selective TYK2 inhibitor for adults with moderate-to-severe plaque psoriasis, marking a significant innovation in treatment options after nearly a decade. The approval follows successful Phase 3 POETYK PSO clinical trials, which showed Sotyktu's superior efficacy over placebo and Otezla® in achieving skin clearance. This breakthrough therapy is anticipated to set a new standard of care and will be available to patients starting September 2022.
Bristol Myers Squibb (NYSE: BMY) is launching its annual Coast 2 Coast 4 Cancer ride, starting from Cannon Beach, Oregon and ending in Long Branch, New Jersey on October 3. Over 126 employees will participate to raise awareness and funding for the V Foundation for Cancer Research. The event has raised over $9.83 million since its inception in 2014, with a target of surpassing $1 million this year. Participants include cancer survivors and those riding in memory of loved ones, with Bristol Myers Squibb matching donations up to $500,000.